Breimer D D, de Boer A G
Arzneimittelforschung. 1976;26(3):448-54.
A sensitive and specific method for the quantitative determination of 5-vinyl-5-(1-methylbutyl)-barbituric acid (vinylbital) in plasma was developed, by using gas chromatography with alkali flame ionization detection. The method is suitable for measuring vinylbital plasma levels in man after administration of therapeutic doses. The pharmacokinetics and relative bioavailability of vinylbital after oral and rectal administration were studied in man. Tablets (Bykonox) containing 150 mg vinylbital, were used for the oral experiments and suppositories (Suppoptanox, polyethylene glycol base) containing 200 mg vinylbital, were used for rectal administration. Six volunteers participated in a cross-over way in the study. Vinylbital plasma concentrations were determined at regular intervals after drug administration. Absorption and elimination of vinylbital appeared to occur according to a single first-order process and the plasma concentrations were fitted by computer according to the equation intrinsic to the one-compartment open model after oral or rectal administration. The lag time was shorter for the suppository than for the tablet, whereas the absorption rate was faster for the tablet (mean absorption half-life 0.24 h compared with 0.64 h for the suppository). The elimination half-life of vinylbital varied from 17.6 to 33.5 h, with a mean value of 23.5 h for oral administration and 23.8 h for rectal administration. The half-lives were not considerably different on the two occasions for the individual volunteers. The average bioavailability of vinylbital for the suppository, relative to the tablet, was approximately 93%. Three volunteers collected their urine during 3--4 days after administration of a tablet. Unchanged vinylbital was determined and approximately 1.6% of the administered dose was excreted as unchanged drug. Some preliminary experiments of repetive vinylbital administration showed that self-induction of metabolism did not occur.
建立了一种灵敏且特异的血浆中5-乙烯基-5-(1-甲基丁基)-巴比妥酸(乙烯比妥)定量测定方法,采用带碱火焰离子化检测的气相色谱法。该方法适用于测定人体服用治疗剂量乙烯比妥后的血浆水平。研究了乙烯比妥在人体口服和直肠给药后的药代动力学及相对生物利用度。口服实验使用含150mg乙烯比妥的片剂(Bykonox),直肠给药使用含200mg乙烯比妥的栓剂(Suppoptanox,聚乙二醇基质)。六名志愿者以交叉方式参与研究。给药后定期测定乙烯比妥血浆浓度。乙烯比妥的吸收和消除似乎按单一一级过程进行,口服或直肠给药后血浆浓度根据一室开放模型的固有方程用计算机拟合。栓剂的滞后时间比片剂短,而片剂的吸收速率更快(平均吸收半衰期0.24小时,栓剂为0.64小时)。乙烯比妥的消除半衰期为17.6至33.5小时,口服给药的平均值为23.5小时,直肠给药为23.8小时。个体志愿者在两种情况下的半衰期没有显著差异。相对于片剂,栓剂中乙烯比妥的平均生物利用度约为93%。三名志愿者在服用一片剂后3至4天收集尿液。测定未变化的乙烯比妥,约1.6%的给药剂量以未变化药物形式排泄。一些乙烯比妥重复给药的初步实验表明未发生代谢的自身诱导。